Efficiency, Safety and Portability of Neovasculgen
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT03068585
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 100 participants
- Sponsor
- Artgen Biotech
- Registry
-
NCT03068585
-
- Other papers using this trial's data
- Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication
- pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT03068585. Randomized; no masking; primary purpose treatment. Start 2010-02 (actual); primary completion 2011-06-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficiency, Safety and Portability of Neovasculgen
- Acronym
- Neovasculgen
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- Neovasculgen (Cambiogeneplasmid)
- Lead sponsor
- Artgen Biotech
Record details
- Record id
cardio:ct-nct03068585- Content hash
93d19d511b8ced8002a3fdda5172ac67e47ff3fa7044849e869681fd6c28a651